Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Recent studies demonstrated that allogeneic hematopoietic stem cell transplantation
(allo-HSCT) could be a valuable treatment choice for mixed-lineage-leukemia (MLL)-rearranged
acute leukemia. Unfortunately, some patients relapsed after allo-HSCT. In this prospective
randomized controlled study, the safety and efficacy of Decitabine + BUCY and BUCY
myeloablative conditioning regimens in MLL+ acute leukemia undergoing allo-HSCT are
evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Guangzhou First People's Hospital Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Third Affiliated Hospital, Sun Yat-Sen University Zhujiang Hospital